

STEMLINE THERAPEUTICS INC
Form 8-K
November 06, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **November 6, 2015**

Stemline Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-35619
(Commission File Number)

45-0522567
(IRS Employer Identification No.)

750 Lexington Avenue

Eleventh Floor

Edgar Filing: STEMLINE THERAPEUTICS INC - Form 8-K

New York, New York 10022

(Address of Principal Executive Offices)

(646) 502-2311

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
 - Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
-

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2015, Stemline Therapeutics, Inc. (Stemline or the Company) issued a press release to announce its financial results for the third quarter ended September 30, 2015. A copy of such press release is being furnished as Exhibit 99.1 to this report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished herewith:

Exhibit Number	Description
99.1	Press release issued by Stemline Therapeutics, Inc., dated November 6, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Stemline Therapeutics, Inc.
(Registrant)

Date: November 6, 2015

By: */s/* Kenneth Hoberman
Kenneth Hoberman
Chief Operating Officer

INDEX TO EXHIBITS

Exhibit Number	Description
99.1	Press release issued by Stemline Therapeutics, Inc., dated November 6, 2015.